Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Serological Immunoglobulin-Free Light Chain Profile in Myasthenia Gravis Patients.

Basile U, Marino M, Napodano C, Pocino K, Alboini PE, Gulli F, Evoli A, Provenzano C, Bartoccioni E.

J Immunol Res. 2018 Mar 25;2018:9646209. doi: 10.1155/2018/9646209. eCollection 2018.

2.

Rituximab in myasthenia gravis: a "to be or not to be" inhibitor of T cell function.

Marino M, Bartoccioni E, Alboini PE, Evoli A.

Ann N Y Acad Sci. 2018 Feb;1413(1):41-48. doi: 10.1111/nyas.13562. Epub 2018 Jan 25. Review.

PMID:
29369382
3.

Myasthenia gravis with antibodies to MuSK: an update.

Evoli A, Alboini PE, Damato V, Iorio R, Provenzano C, Bartoccioni E, Marino M.

Ann N Y Acad Sci. 2018 Jan;1412(1):82-89. doi: 10.1111/nyas.13518. Epub 2017 Dec 21. Review.

PMID:
29266255
4.

Diagnostics of autoimmune encephalitis associated with antibodies against neuronal surface antigens.

Zuliani L, Zoccarato M, Gastaldi M, Iorio R, Evoli A, Biagioli T, Casagrande S, Bazzigaluppi E, Fazio R, Giannotta C, Nobile-Orazio E, Andreetta F, Simoncini O, Costa G, Mariotto S, Ferrari S, Galloni E, Marcon M, Franciotta D, Giometto B.

Neurol Sci. 2017 Oct;38(Suppl 2):225-229. doi: 10.1007/s10072-017-3032-4. Review.

PMID:
29030767
5.

Diagnostics of paraneoplastic neurological syndromes.

Zoccarato M, Gastaldi M, Zuliani L, Biagioli T, Brogi M, Bernardi G, Corsini E, Bazzigaluppi E, Fazio R, Giannotta C, Nobile-Orazio E, Costa G, Iorio R, Evoli A, Mariotto S, Ferrari S, Galloni E, De Riva V, Zardini E, Franciotta D, Giometto B.

Neurol Sci. 2017 Oct;38(Suppl 2):237-242. doi: 10.1007/s10072-017-3031-5. Review.

PMID:
29030766
6.

Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients.

Iorio R, Damato V, Evoli A, Gessi M, Gaudino S, Di Lazzaro V, Spagni G, Sluijs JA, Hol EM.

J Neurol Neurosurg Psychiatry. 2018 Feb;89(2):138-146. doi: 10.1136/jnnp-2017-316583. Epub 2017 Sep 26.

PMID:
28951498
7.

Immune checkpoint inhibitor therapy: A double-edged sword?

Kim HJ, Evoli A.

Neurology. 2017 Sep 12;89(11):1101-1102. doi: 10.1212/WNL.0000000000004369. Epub 2017 Aug 18. No abstract available.

PMID:
28821690
8.

Myasthenia gravis: new developments in research and treatment.

Evoli A.

Curr Opin Neurol. 2017 Oct;30(5):464-470. doi: 10.1097/WCO.0000000000000473. Review.

PMID:
28654435
9.

IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG.

Huda S, Waters P, Woodhall M, Leite MI, Jacobson L, De Rosa A, Maestri M, Ricciardi R, Heckmann JM, Maniaol A, Evoli A, Cossins J, Hilton-Jones D, Vincent A.

Neurol Neuroimmunol Neuroinflamm. 2017 Jun 5;4(4):e357. doi: 10.1212/NXI.0000000000000357. eCollection 2017 Jul.

10.

Pattern of ocular involvement in myasthenia gravis with MuSK antibodies.

Evoli A, Alboini PE, Iorio R, Damato V, Bartoccioni E.

J Neurol Neurosurg Psychiatry. 2017 Sep;88(9):761-763. doi: 10.1136/jnnp-2017-315782. Epub 2017 Jun 10.

PMID:
28601810
11.

Rituximab in Neuromyelitis Optica Spectrum Disorders-Reply: Why Not as First-Line Therapy.

Damato V, Evoli A, Iorio R.

JAMA Neurol. 2017 Apr 1;74(4):482-483. doi: 10.1001/jamaneurol.2016.5936. No abstract available.

PMID:
28166310
12.

Remission of myasthenia gravis with MuSK antibodies during ruxolitinib treatment.

Alboini PE, Evoli A, Damato V, Iorio R, Bartoccioni E.

Muscle Nerve. 2017 Mar;55(3):E12-E13. doi: 10.1002/mus.25458. Epub 2016 Nov 25. No abstract available.

PMID:
27808416
13.

Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis.

Damato V, Evoli A, Iorio R.

JAMA Neurol. 2016 Nov 1;73(11):1342-1348. doi: 10.1001/jamaneurol.2016.1637. Review.

PMID:
27668357
14.

Randomized Trial of Thymectomy in Myasthenia Gravis.

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BR, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Garcia Ramos GS, Verschuuren JJ, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Conwit R, Odenkirchen J, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group.

N Engl J Med. 2016 Aug 11;375(6):511-22. doi: 10.1056/NEJMoa1602489. Erratum in: N Engl J Med. 2017 May 25;376(21):2097. [Dosage error in article text].

15.

International consensus guidance for management of myasthenia gravis: Executive summary.

Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P.

Neurology. 2016 Jul 26;87(4):419-25. doi: 10.1212/WNL.0000000000002790. Epub 2016 Jun 29. Review.

16.

Molecular genetic alterations in egfr CA-SSR-1 microsatellite and egfr copy number changes are associated with aggressiveness in thymoma.

Conti S, Gallo E, Sioletic S, Facciolo F, Palmieri G, Lauriola L, Evoli A, Martucci R, Di Benedetto A, Novelli F, Giannarelli D, Deriu G, Granone P, Ottaviano M, Muti P, Pescarmona E, Marino M.

J Thorac Dis. 2016 Mar;8(3):386-95. doi: 10.21037/jtd.2016.02.40.

17.

Titin antibodies in "seronegative" myasthenia gravis--A new role for an old antigen.

Stergiou C, Lazaridis K, Zouvelou V, Tzartos J, Mantegazza R, Antozzi C, Andreetta F, Evoli A, Deymeer F, Saruhan-Direskeneli G, Durmus H, Brenner T, Vaknin A, Berrih-Aknin S, Behin A, Sharshar T, De Baets M, Losen M, Martinez-Martinez P, Kleopa KA, Zamba-Papanicolaou E, Kyriakides T, Kostera-Pruszczyk A, Szczudlik P, Szyluk B, Lavrnic D, Basta I, Peric S, Tallaksen C, Maniaol A, Gilhus NE, Casasnovas Pons C, Pitha J, Jakubíkova M, Hanisch F, Bogomolovas J, Labeit D, Labeit S, Tzartos SJ.

J Neuroimmunol. 2016 Mar 15;292:108-15. doi: 10.1016/j.jneuroim.2016.01.018. Epub 2016 Jan 27.

PMID:
26943968
18.

Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis.

Punga T, Bartoccioni E, Lewandowska M, Damato V, Evoli A, Punga AR.

J Neuroimmunol. 2016 Mar 15;292:21-6. doi: 10.1016/j.jneuroim.2016.01.003. Epub 2016 Jan 7.

19.

3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies.

Evoli A, Alboini PE, Damato V, Iorio R.

Neurology. 2016 Mar 15;86(11):1070-1. doi: 10.1212/WNL.0000000000002466. Epub 2016 Feb 12. No abstract available.

PMID:
26873957
20.

Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity.

Huijbers MG, Vink AF, Niks EH, Westhuis RH, van Zwet EW, de Meel RH, Rojas-García R, Díaz-Manera J, Kuks JB, Klooster R, Straasheijm K, Evoli A, Illa I, van der Maarel SM, Verschuuren JJ.

J Neuroimmunol. 2016 Feb 15;291:82-8. doi: 10.1016/j.jneuroim.2015.12.016. Epub 2016 Jan 5.

PMID:
26857500
21.

Overcoming challenges in the diagnosis and treatment of myasthenia gravis.

Evoli A, Iorio R, Bartoccioni E.

Expert Rev Clin Immunol. 2016;12(2):157-68. doi: 10.1586/1744666X.2016.1110487. Epub 2015 Dec 16. Review.

PMID:
26675896
22.

Flow Cytofluorimetric Analysis of Anti-LRP4 (LDL Receptor-Related Protein 4) Autoantibodies in Italian Patients with Myasthenia Gravis.

Marino M, Scuderi F, Samengo D, Saltelli G, Maiuri MT, Shen C, Mei L, Sabatelli M, Pani G, Antonini G, Evoli A, Bartoccioni E.

PLoS One. 2015 Aug 18;10(8):e0135378. doi: 10.1371/journal.pone.0135378. eCollection 2015.

23.

Prognostic grading after complete resection for thymic malignancies.

Lococo F, Cafarotti S, Cesario A, Dall'Armi V, Cusumano G, Lauriola L, Frederic M, Evoli A, Margaritora S, Granone P.

Eur Rev Med Pharmacol Sci. 2015 Aug;19(15):2882-91.

24.

Myasthenia gravis with presynaptic neurophysiological signs: Two case reports and literature review.

Alboini PE, Damato V, Iorio R, Luigetti M, Evoli A.

Neuromuscul Disord. 2015 Aug;25(8):646-50. doi: 10.1016/j.nmd.2015.04.012. Epub 2015 May 5. Review.

PMID:
26028274
25.

MuSK autoantibodies in myasthenia gravis detected by cell based assay--A multinational study.

Tsonis AI, Zisimopoulou P, Lazaridis K, Tzartos J, Matsigkou E, Zouvelou V, Mantegazza R, Antozzi C, Andreetta F, Evoli A, Deymeer F, Saruhan-Direskeneli G, Durmus H, Brenner T, Vaknin A, Berrih-Aknin S, Behin A, Sharshar T, De Baets M, Losen M, Martinez-Martinez P, Kleopa KA, Zamba-Papanicolaou E, Kyriakides T, Kostera-Pruszczyk A, Szczudlik P, Szyluk B, Lavrnic D, Basta I, Peric S, Tallaksen C, Maniaol A, Casasnovas Pons C, Pitha J, Jakubíkova M, Hanisch F, Tzartos SJ.

J Neuroimmunol. 2015 Jul 15;284:10-7. doi: 10.1016/j.jneuroim.2015.04.015. Epub 2015 Apr 27.

PMID:
26025053
26.

Poly-autoimmunity in patients with myasthenia gravis: A single-center experience.

Evoli A, Caliandro P, Iorio R, Alboini PE, Damato V, LaTorre G, Provenzano C, Marino M, Lauriola L, Scuderi F, Bartoccioni E.

Autoimmunity. 2015;48(6):412-7. doi: 10.3109/08916934.2015.1031890. Epub 2015 Apr 14.

PMID:
25868386
27.

Characterization of B cells in muscle-specific kinase antibody myasthenia gravis.

Guptill JT, Yi JS, Sanders DB, Guidon AC, Juel VC, Massey JM, Howard JF Jr, Scuderi F, Bartoccioni E, Evoli A, Weinhold KJ.

Neurol Neuroimmunol Neuroinflamm. 2015 Feb 26;2(2):e77. doi: 10.1212/NXI.0000000000000077. eCollection 2015 Apr.

28.

A genome-wide association study of myasthenia gravis.

Renton AE, Pliner HA, Provenzano C, Evoli A, Ricciardi R, Nalls MA, Marangi G, Abramzon Y, Arepalli S, Chong S, Hernandez DG, Johnson JO, Bartoccioni E, Scuderi F, Maestri M, Gibbs JR, Errichiello E, Chiò A, Restagno G, Sabatelli M, Macek M, Scholz SW, Corse A, Chaudhry V, Benatar M, Barohn RJ, McVey A, Pasnoor M, Dimachkie MM, Rowin J, Kissel J, Freimer M, Kaminski HJ, Sanders DB, Lipscomb B, Massey JM, Chopra M, Howard JF Jr, Koopman WJ, Nicolle MW, Pascuzzi RM, Pestronk A, Wulf C, Florence J, Blackmore D, Soloway A, Siddiqi Z, Muppidi S, Wolfe G, Richman D, Mezei MM, Jiwa T, Oger J, Drachman DB, Traynor BJ.

JAMA Neurol. 2015 Apr;72(4):396-404. doi: 10.1001/jamaneurol.2014.4103.

29.

Paraneoplastic disorders in thymoma patients.

Evoli A, Lancaster E.

J Thorac Oncol. 2014 Sep;9(9 Suppl 2):S143-7. doi: 10.1097/JTO.0000000000000300. Review.

30.

Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.

Iorio R, Damato V, Alboini PE, Evoli A.

J Neurol. 2015 May;262(5):1115-9. doi: 10.1007/s00415-014-7532-3. Epub 2014 Oct 12. Review.

PMID:
25308632
31.

The detection of neural autoantibodies in patients with antiepileptic-drug-resistant epilepsy predicts response to immunotherapy.

Iorio R, Assenza G, Tombini M, Colicchio G, Della Marca G, Benvenga A, Damato V, Rossini PM, Vollono C, Plantone D, Marti A, Batocchi AP, Evoli A.

Eur J Neurol. 2015 Jan;22(1):70-8. doi: 10.1111/ene.12529. Epub 2014 Aug 12.

PMID:
25112548
32.

Diagnostic features and subtyping of thymoma lymph node metastases.

Sioletic S, Lauriola L, Gallo E, Martucci R, Evoli A, Palmieri G, Melis E, Pizzi G, Rinaldi M, Lalle M, Pescarmona E, Granone P, Facciolo F, Marino M.

Biomed Res Int. 2014;2014:546149. doi: 10.1155/2014/546149. Epub 2014 Jul 8.

33.

Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study.

Lattanzio R, La Sorda R, Facciolo F, Sioletic S, Lauriola L, Martucci R, Gallo E, Palmieri G, Evoli A, Alessandrini G, Ruco L, Rendina EA, Truini M, Chiarle R, Barreca A, Pich A, Ascani S, Remotti D, Tunesi G, Granone P, Ratto GB, Puma F, Pescarmona E, Piantelli M, Marino M; Thymic Epithelial Tumor Working Group, Carlini S, Cerasoli V, Corzani F, Melis E, Filippetti M, Canalini P, Palestro G, Lalle M, Ruffini E, Ceribelli A, Rinaldi M.

Lung Cancer. 2014 Aug;85(2):191-6. doi: 10.1016/j.lungcan.2014.05.010. Epub 2014 May 22.

34.

SFEMG: A piece in the diagnostic puzzle of myasthenia.

Padua L, Caliandro P, Di Iasi G, Pazzaglia C, Ciaraffa F, Evoli A.

Clin Neurophysiol. 2014 Nov;125(11):2318-9. doi: 10.1016/j.clinph.2014.03.008. Epub 2014 Mar 17. No abstract available.

PMID:
24745337
35.

When myasthenia gravis is not all.

Damato V, Alboini PE, Mastrorosa A, Dickmann A, Colosimo C, Evoli A.

J Neurol. 2014 Apr;261(4):835-6. doi: 10.1007/s00415-014-7307-x. Epub 2014 Mar 15. No abstract available.

PMID:
24627110
36.

Thymectomy in myasthenia gravis: proposal for a predictive score of postoperative myasthenic crisis.

Leuzzi G, Meacci E, Cusumano G, Cesario A, Chiappetta M, Dall'armi V, Evoli A, Costa R, Lococo F, Primieri P, Margaritora S, Granone P.

Eur J Cardiothorac Surg. 2014 Apr;45(4):e76-88; discussion e88. doi: 10.1093/ejcts/ezt641. Epub 2014 Feb 12.

PMID:
24525106
37.

Lower motor neuron involvement in longitudinally extensive transverse myelitis with and without aquaporin-4 antibodies.

Luigetti M, Lo Monaco M, Evoli A, Mirabella M, Damato V, Iorio R.

Clin Neurophysiol. 2014 Sep;125(9):1925-6. doi: 10.1016/j.clinph.2013.12.116. Epub 2014 Jan 27. No abstract available.

PMID:
24525092
38.

Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management.

Evoli A, Liguori R, Romani A, Mantegazza R, Di Muzio A, Giometto B, Pegoraro E, Rodolico C, Vigliani MC; Italian Working Group on Myasthenic Syndromes.

Neurol Sci. 2014 Apr;35(4):515-20. doi: 10.1007/s10072-014-1637-4. Epub 2014 Jan 31. Review.

PMID:
24481713
39.

EFNS/ENS Guidelines for the treatment of ocular myasthenia.

Kerty E, Elsais A, Argov Z, Evoli A, Gilhus NE.

Eur J Neurol. 2014 May;21(5):687-93. doi: 10.1111/ene.12359. Epub 2014 Jan 28. Review.

PMID:
24471489
40.

T cell repertoire in DQ5-positive MuSK-positive myasthenia gravis patients.

Marino M, Maiuri MT, Di Sante G, Scuderi F, La Carpia F, Trakas N, Provenzano C, Zisimopoulou P, Ria F, Tzartos SJ, Evoli A, Bartoccioni E.

J Autoimmun. 2014 Aug;52:113-21. doi: 10.1016/j.jaut.2013.12.007. Epub 2014 Jan 4.

PMID:
24397960
41.

A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis.

Zisimopoulou P, Evangelakou P, Tzartos J, Lazaridis K, Zouvelou V, Mantegazza R, Antozzi C, Andreetta F, Evoli A, Deymeer F, Saruhan-Direskeneli G, Durmus H, Brenner T, Vaknin A, Berrih-Aknin S, Frenkian Cuvelier M, Stojkovic T, DeBaets M, Losen M, Martinez-Martinez P, Kleopa KA, Zamba-Papanicolaou E, Kyriakides T, Kostera-Pruszczyk A, Szczudlik P, Szyluk B, Lavrnic D, Basta I, Peric S, Tallaksen C, Maniaol A, Tzartos SJ.

J Autoimmun. 2014 Aug;52:139-45. doi: 10.1016/j.jaut.2013.12.004. Epub 2013 Dec 24.

PMID:
24373505
42.

Reliability of SFEMG in diagnosing myasthenia gravis: sensitivity and specificity calculated on 100 prospective cases.

Padua L, Caliandro P, Di Iasi G, Pazzaglia C, Ciaraffa F, Evoli A.

Clin Neurophysiol. 2014 Jun;125(6):1270-3. doi: 10.1016/j.clinph.2013.11.005. Epub 2013 Nov 15.

PMID:
24296278
43.

Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies.

Iorio R, Damato V, Mirabella M, Evoli A, Marti A, Plantone D, Frisullo G, Batocchi AP.

J Neurol. 2013 Sep;260(9):2396-402. doi: 10.1007/s00415-013-6997-9. Epub 2013 Jun 21.

PMID:
23793787
44.

Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis.

Catzola V, Battaglia A, Buzzonetti A, Fossati M, Scuderi F, Fattorossi A, Evoli A.

J Neurol. 2013 Aug;260(8):2163-5. doi: 10.1007/s00415-013-6987-y. Epub 2013 Jun 8. No abstract available.

PMID:
23749295
45.

The tiles make a puzzle but the single tile is not the puzzle: the need for a global assessment of the patient.

Caliandro P, Padua L, Evoli A.

Clin Neurophysiol. 2013 Sep;124(9):1712-3. doi: 10.1016/j.clinph.2013.03.011. Epub 2013 Apr 28. No abstract available.

PMID:
23631895
46.

Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase.

Evoli A, Padua L.

Autoimmun Rev. 2013 Jul;12(9):931-5. doi: 10.1016/j.autrev.2013.03.004. Epub 2013 Mar 25. Review.

PMID:
23535158
47.

Management challenges in muscle-specific tyrosine kinase myasthenia gravis.

Evoli A, Alboini PE, Bisonni A, Mastrorosa A, Bartoccioni E.

Ann N Y Acad Sci. 2012 Dec;1274:86-91. doi: 10.1111/j.1749-6632.2012.06781.x. Erratum in: Ann N Y Acad Sci. 2013 Apr;1283:102. Bartocccioni, Emanuela [corrected to Bartoccioni, Emanuela].

PMID:
23252901
48.

A B3 type-thymoma in a 7-year-old child with myasthenia gravis.

Iorio R, Evoli A, Lauriola L, Batocchi AP.

J Thorac Oncol. 2012 May;7(5):937-8. doi: 10.1097/JTO.0b013e31824cbb18. No abstract available.

49.

Spontaneous recovery from anti-NMDAR encephalitis.

Evoli A, Spinelli P, Frisullo G, Alboini PE, Servidei S, Marra C.

J Neurol. 2012 Sep;259(9):1964-6. doi: 10.1007/s00415-012-6457-y. Epub 2012 Mar 3. No abstract available.

PMID:
22392580
50.

PTPN22 and myasthenia gravis: replication in an Italian population and meta-analysis of literature data.

Provenzano C, Ricciardi R, Scuderi F, Maiuri MT, Maestri M, La Carpia F, Sferrazza A, Marino M, Leone L, Lucchi M, Mussi A, Zollino M, Evoli A, Bartoccioni E.

Neuromuscul Disord. 2012 Feb;22(2):131-8. doi: 10.1016/j.nmd.2011.09.003. Epub 2011 Dec 24.

PMID:
22197427

Supplemental Content

Support Center